Artesunate alleviates psoriasis‐like dermatitis by reducing interleukin‐23 expression in tumor necrosis factor‐alpha‐induced HaCaT cells
Clinical and Experimental Pharmacology and Physiology · 2023
DOI: 10.1111/1440-1681.13816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2023. Verfasst von Lixian Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Psoriasis, Artesunate, Tumor Necrosis Factor-alpha, Interleukin-23. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: the Science and Technology Program of Guangzhou, China, the Skin Research Program from Guangdong Medical Doctor Association, Natural Science Foundation of Guangdong Province, China.
Abstract (Originalsprache)
Artesunate (ART), an antimalarial drug with a multifunctional immunomodulatory effect, reduces psoriasis disease. ART can alleviate psoriasis‐like dermatitis in mice but has no effect on proinflammatory cytokines in the blood. Thus, we hypothesized that the skin might be the target tissue of ART during the treatment of psoriasis. The interleukin (IL)‐23/IL‐17 axis has a key role in the pathogenesis of psoriasis. However, whether and how ART manipulates the IL‐23 signal during psoriasis is unknown. This study found that IL‐23 is highly expressed in the epidermis of psoriasis lesions and positively correlated with histological neutrophil infiltration and clinical psoriasis area and severity index (PASI) scores. Furthermore, ART inhibits the migration and cell cycle, as well as tumor necrosis factor‐alpha (TNF‐α)‐induced IL‐23 expression in HaCaT cells in a dose‐dependent manner, probably through interference with the nuclear factor kappa B (NF‐κB) signalling pathway. Animal experiments in imiquimod (IMQ)‐induced psoriasis‐like mice model also suggested that ART dose‐dependently reduces IL‐23 in the epidermis and ameliorates neutrophil infiltration. These findings thus provide further molecular evidence supporting ART as a promising drug for psoriasis in clinic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
- Department of Dermatology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
ORCID-Profile: Lixian Lin, Zhixuan Guo
Förderung
- the Science and Technology Program of Guangzhou, China
- the Skin Research Program from Guangdong Medical Doctor Association
- Natural Science Foundation of Guangdong Province, China
- Guangdong Basic and Applied Basic Research Fundation
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Lin, L., Huang, Z., Jianchi, M., Guo, Z., Shi, Z., Tang, Z., Guo, Q., & Xiong, H. (2023). Artesunate alleviates psoriasis‐like dermatitis by reducing interleukin‐23 expression in tumor necrosis factor‐alpha‐induced HaCaT cells. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.13816
Vancouver
Lin L, Huang Z, Jianchi M, Guo Z, Shi Z, Tang Z, et al. Artesunate alleviates psoriasis‐like dermatitis by reducing interleukin‐23 expression in tumor necrosis factor‐alpha‐induced HaCaT cells. Clinical and Experimental Pharmacology and Physiology. 2023. doi:10.1111/1440-1681.13816
BibTeX
@article{Lin2023,
author = {Lin, Lixian and Huang, Zhongzhou and Jianchi, Ma and Guo, Zhixuan and Shi, Zhenrui and Tang, Zengqi and Guo, Qing and Xiong, Hui},
title = {Artesunate alleviates psoriasis‐like dermatitis by reducing interleukin‐23 expression in tumor necrosis factor‐alpha‐induced HaCaT cells},
journal = {Clinical and Experimental Pharmacology and Physiology},
year = {2023},
doi = {10.1111/1440-1681.13816}
}
EUVIMED